Company in focus: Modus Therapeutics

Swedish drug development company Modus Therapeutics has had a busy year, and 2019 could take them one step closer to having sevuparin on the market. In 2016 the clinical-stage drug development and Karolinska Development portfolio company Dilaforette Holding changed its name to Modus Therapeutics Holding. The move signified the company’s emancipation from its parent company … Continue reading Company in focus: Modus Therapeutics